Privatizing biomedical research—a 'third way'

The allocation of risks and benefits of publicly sponsored biomedical research is becoming increasingly skewed toward for-profit entities and against the public interest. A legitimate solution to this imbalance would be to levy compulsory government royalty fees on commercial products made possible...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature biotechnology 2008, Vol.26 (1), p.31-36
Hauptverfasser:	Bouchard, Ron A, Lemmens, Trudo
Format:	Artikel
Sprache:	eng
Schlagworte:	Agriculture Bioinformatics Biomedical and Life Sciences Biomedical Engineering/Biotechnology Biomedical research Biomedical Research - organization & administration Biomedicine Biotechnology Canada commentary Government Licensure - trends Life Sciences Private Sector - organization & administration Privatization Public concern Royalties Technology Transfer
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The allocation of risks and benefits of publicly sponsored biomedical research is becoming increasingly skewed toward for-profit entities and against the public interest. A legitimate solution to this imbalance would be to levy compulsory government royalty fees on commercial products made possible by public efforts.
ISSN:	1087-0156 1546-1696
DOI:	10.1038/nbt0108-31